R1 RCM RCM underwent analysis by 13 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 4 | 5 | 4 | 0 | 0 |
Last 30D | 1 | 0 | 0 | 0 | 0 |
1M Ago | 2 | 2 | 1 | 0 | 0 |
2M Ago | 1 | 3 | 3 | 0 | 0 |
3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $16.31, with a high estimate of $20.00 and a low estimate of $14.00. This upward trend is apparent, with the current average reflecting a 8.73% increase from the previous average price target of $15.00.
Deciphering Analyst Ratings: An In-Depth Analysis
In examining recent analyst actions, we gain insights into how financial experts perceive R1 RCM. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Jack Wallace | Guggenheim | Lowers | Buy | $15.00 | $17.00 |
Jailendra Singh | Truist Securities | Maintains | Hold | $16.00 | $16.00 |
Craig Hettenbach | Morgan Stanley | Maintains | Overweight | $17.00 | $17.00 |
Richard Close | Canaccord Genuity | Lowers | Buy | $16.00 | $17.00 |
Daniel Grosslight | Citigroup | Announces | Buy | $16.00 | - |
Sean Dodge | RBC Capital | Maintains | Outperform | $19.00 | - |
Sarah James | Cantor Fitzgerald | Maintains | Overweight | $20.00 | - |
Jailendra Singh | Truist Securities | Announces | Hold | $16.00 | - |
Daniel Grosslight | Citigroup | Raises | Buy | $16.00 | $14.00 |
Scott Schoenhaus | Keybanc | Raises | Overweight | $17.00 | $13.00 |
Stephanie Davis | Barclays | Maintains | Equal-Weight | $14.00 | $14.00 |
Elizabeth Anderson | Evercore ISI Group | Raises | In-Line | $16.00 | $12.00 |
Michael Cherny | Leerink Partners | Announces | Outperform | $14.00 | - |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to R1 RCM. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of R1 RCM compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for R1 RCM's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of R1 RCM's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on R1 RCM analyst ratings.
All You Need to Know About R1 RCM
R1 RCM Inc is a provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers. Its services help healthcare providers generate sustainable improvements in their operating margins and cash flows while also enhancing patient, physician, and staff satisfaction for the customers, Its service offering consists of end-to-end RCM services for health systems, hospitals, and physician groups that provide comprehensive revenue cycle infrastructure to providers, including all revenue cycle personnel, technology solutions, and process workflow. The majority of the revenue comes from the operating fees received.
R1 RCM's Economic Impact: An Analysis
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: R1 RCM's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 7.84%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 0.24%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 0.05%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): R1 RCM's ROA stands out, surpassing industry averages. With an impressive ROA of 0.03%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.63, R1 RCM adopts a prudent financial strategy, indicating a balanced approach to debt management.
How Are Analyst Ratings Determined?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.